Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Derivatives -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (341)	8/8/1999 5:17:00 AM
From: SnowShredder	Read Replies (1) \| Respond to of 555

Hi David, I read this on the Yahoo board...Best of luck, Where'd He Go? News on ALKS by: Zoiks5 295 of 296 Alkermes stock rises on drug trial report (Boston Globe 08/05/99) Shares of drug delivery company Alkermes Inc. rose nearly 15 percent following an analyst's report of progress on a schizophrenia drug being developed with Johnson & Johnson. The two firms have entered phase 3 trials in development of a longer-acting version of Johnson & Johnson's Risperdal, the leading antipsychotic drug for schizophrenia, according to a research report released by BancBoston Robertson Stephens. The two companies will present the complete results of the phase 2 trial on Medisorb Risperdal at the World Congress of Psychiatry on Aug. 9. Shares of Cambridge-based Alkermes rose 37/8 to 297/8 and have increased 35 percent so far this year. -------------------------------------------------------------------------------- Posted: 08/06/1999 09:08 am EDT as a reply to: Msg 289 by oldbio View Replies to this Message